Compare Pfizer Inc (PFE) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Schlumberger NV — how do they compare? Pfizer Inc trades at $28.22 (market cap $158.56B), while Schlumberger NV trades at $48.71 (market cap $72.69B). The key difference: Pfizer Inc is far larger — about 2.2× Schlumberger NV's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Schlumberger NV for 99 Days on average.
| PFE | SLB | |
|---|---|---|
Market Cap | $158.56B | $72.69B |
Volume | 44,138,282 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $29.02 | $60.10 |
52-Week Low | $23.67 | $31.72 |
Typical Hold Time | 158 Days | 99 Days |
Enterprise Value | $210.06B | $81.42B |
Dividend Yield | 6.18% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
SLB trades at $48.91, up 1.98% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 8.53% net margin and 13.37% ROE, supported by recent contract wins in Saudi Arabia and Mozambique. Revenue declined slightly to $35.71B in 2025, but operating cash flow remains robust at $6.49B. Analyst consensus is strongly bullish with 85% buy ratings and $64.58 price target, representing 32% upside potential.
SLB presents a compelling value opportunity with strong fundamentals and positive analyst sentiment, though technical indicators suggest near-term weakness. The stock's current valuation at 23.89 P/E appears reasonable given the company's contract momentum and global energy technology leadership. Key risks include energy price volatility and execution challenges in new projects, but the dividend yield and institutional support provide downside protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
